This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Spruce Biosciences’ Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B

Ticker(s): SPRB

Who's the expert?

University Medical Center Hamburg-Eppendorf (UKE) and International Center for Lysosomal Disorders / European Study Group on Lysosomal Diseases (ESGLD)

  • Head of the Lysosomal Disease Unit and Principal Investigator at the International Center for Lysosomal Disorders at UKE and Working Group Leader of the European Study Group on Lysosomal Diseases (ESGLD)
  • Manages dozens of patients with San Fillipino Syndrome and other lysosomal diseases
  • Senior physician and medical specialist in Pediatrics and Youth Medicine with a clinical focus on rare metabolic and lysosomal storage disorders, including mucopolysaccharidoses, Sanfilippo syndrome, and other inherited metabolic conditions

Interview Goal
To gain a deeper understanding of Spruce Biosciences’ Tralesinidase Alfa (TA-ERT) as a potential treatment for Sanfilippo Syndrome Type B

Are You Interested In These Questions?

Slingshot Insights Explained
4Days Left to Join Project
Call Date
Feb 09, 2026
Call Time
10:00 AM EST
Wall Street Time

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.